Royalty Pharma plc (NASDAQ:RPRX) Receives $41.67 Consensus Price Target from Analysts

Shares of Royalty Pharma plc (NASDAQ:RPRX) have earned an average rating of “Buy” from the seven ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $41.67.

A number of research analysts have issued reports on the company. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. Finally, Citigroup decreased their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Swedbank AB boosted its position in shares of Royalty Pharma by 2.0% during the 3rd quarter. Swedbank AB now owns 11,027,370 shares of the biopharmaceutical company’s stock valued at $311,964,000 after acquiring an additional 213,900 shares in the last quarter. State Street Corp raised its holdings in Royalty Pharma by 0.3% during the 3rd quarter. State Street Corp now owns 9,516,262 shares of the biopharmaceutical company’s stock worth $269,215,000 after purchasing an additional 29,451 shares during the last quarter. Geode Capital Management LLC boosted its stake in Royalty Pharma by 6.1% in the third quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company’s stock valued at $205,562,000 after acquiring an additional 417,490 shares during the last quarter. Two Sigma Advisers LP boosted its position in shares of Royalty Pharma by 44.7% in the 3rd quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock worth $85,809,000 after purchasing an additional 936,900 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Royalty Pharma by 58.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company’s stock valued at $84,915,000 after acquiring an additional 1,103,341 shares during the period. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Trading Up 0.1 %

Shares of NASDAQ:RPRX opened at $30.03 on Friday. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.64. The company’s 50-day moving average price is $26.05 and its 200 day moving average price is $27.09. The company has a market cap of $17.69 billion, a PE ratio of 15.56, a P/E/G ratio of 4.36 and a beta of 0.47. Royalty Pharma has a fifty-two week low of $24.05 and a fifty-two week high of $31.66.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.93%. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Friday, February 21st. Royalty Pharma’s dividend payout ratio is 45.60%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.